1. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
- Author
-
Gong, Jun, Posadas, Edwin M., Bhowmick, Neil, Kim, Hyung L., Daskivich, Timothy J., Gupta, Amit, Sandler, Howard M., Kamrava, Mitchell, Zumsteg, Zachary S., Freedland, Stephen J., and Figlin, Robert A.
- Subjects
United States. Food and Drug Administration ,Prostate cancer -- Drug therapy -- Genetic aspects ,Metastasis -- Genetic aspects -- Drug therapy ,Antineoplastic agents ,Cancer -- Prevention ,DNA damage -- Genetic aspects ,Antimitotic agents ,Health ,Cedars-Sinai Medical Center - Abstract
DNA-damage repair (DDR) pathway mutations can sensitize cancer cells to a class of cancer therapeutics known as PARP inhibitors. Given that DDR alterations can be found in up to one-third of advanced prostate cancers, PARP inhibitors have recently been established in treatment-refractory settings. We provide an updated review of the clinical data supporting the 4 PARP inhibitors that have undergone the most investigation thus far in metastatic castrate-resistant prostate cancer (mCRPC). Two of these agents are currently approved for the treatment of DDR-altered mCRPC. We end with a discussion on integration of approved PARP inhibitors into advanced prostate cancer clinical practice. KEYWORDS: Prostate cancer, androgen inhibition, poly(ADP) ribose polymerase, PARP inhibitors, DNA damage repair, BRCA, homologous recombination, Introduction Prostate cancer represents the most commonly diagnosed cancer and second-leading cause of cancer death in US men, with a projected 191,930 new cases and 33,330 deaths in 2020. (1) [...]
- Published
- 2021